The cost-effectiveness of tuberculosis preventive therapy for HIV-infected individuals in southern India: a trial-based analysis.

PloS One
Mai Tuyet PhoRochelle P Walensky

Abstract

Regimens for isoniazid-based preventive therapy (IPT) for tuberculosis (TB) in HIV-infected individuals have not been widely adopted given concerns regarding efficacy, adherence and drug resistance. Further, the cost-effectiveness of IPT has not been studied in India. We used an HIV/TB model to project TB incidence, life expectancy, cost and incremental cost-effectiveness of six months of isoniazid plus ethambutol (6EH), thirty-six months of isoniazid (36H) and no IPT for HIV-infected patients in India. Model input parameters included a median CD4 count of 324 cells/mm(3), and a rate ratio of developing TB of 0.35 for 6EH and 0.22 for 36H at three years as compared to no IPT. Results of 6EH and 36H were also compared to six months of isoniazid (6H), three months of isoniazid plus rifampin (3RH) and three months of isoniazid plus rifapentine (3RPTH). Projected TB incidence decreased in the 6EH and 36H regimens by 51% and 62% respectively at three-year follow-up compared to no IPT. Without IPT, projected life expectancy was 136.1 months at a lifetime per person cost of $5,630. 6EH increased life expectancy by 0.8 months at an additional per person cost of $100 (incremental cost-effectiveness ratio (ICER) of $1,490/year of life sa...Continue Reading

References

Jun 15, 1997·Annals of Internal Medicine·J W MellorsC R Rinaldo
May 18, 2000·JAMA : the Journal of the American Medical Association·M A EspinalM C Raviglione
Mar 15, 2001·The New England Journal of Medicine·K A FreedbergS J Goldie
Jan 27, 2005·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Jialun ZhouUNKNOWN TREAT Asia HIV Observational Database
Oct 19, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·N KumarasamyKenneth H Mayer
Aug 1, 2006·Bulletin of the World Health Organization·Harry Peter HauslerPeter Godfrey-Faussett
Feb 20, 2007·Bulletin of the World Health Organization·Albert MingaUNKNOWN ANRS 1220 Study Group
Mar 23, 2007·The New England Journal of Medicine·Robert Steinbrook
Jan 11, 2008·AIDS Research and Human Retroviruses·Catherine SeylerXavier Anglaret
Feb 8, 2008·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Rochelle P WalenskyA David Paltiel
Feb 12, 2009·Journal of Biosciences·Soumya Swaminathan, G Nagendran
Jun 16, 2009·Biologicals : Journal of the International Association of Biological Standardization· Who
Jan 22, 2010·The Cochrane Database of Systematic Reviews·Christopher AkoloJimmy Volmink
Jan 23, 2010·Biologicals : Journal of the International Association of Biological Standardization·UNKNOWN WHO
Apr 10, 2010·American Journal of Respiratory and Critical Care Medicine·Zegabriel TedlaTaraz Samandari
Apr 20, 2010·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Andrea A Howard, Wafaa M El-Sadr
Jun 16, 2010·Tropical Medicine & International Health : TM & IH·Giovanni Battista MiglioriAlimuddin Zumla
Sep 24, 2010·PloS One·Lauren M UhlerUNKNOWN CEPAC International investigators
Nov 26, 2010·JPEN. Journal of Parenteral and Enteral Nutrition·Charlene Compher
Dec 7, 2010·Vaccine·UNKNOWN WHO Publication
Jul 8, 2011·The New England Journal of Medicine·Neil A MartinsonRichard E Chaisson
Dec 14, 2011·The New England Journal of Medicine·Timothy R SterlingUNKNOWN TB Trials Consortium PREVENT TB Study Team

❮ Previous
Next ❯

Citations

Jan 25, 2014·Expert Review of Anti-infective Therapy·Soumya Swaminathan, Padmapriyadarsini Chandrasekaran
Jul 19, 2015·Archivos de bronconeumología·Isabel Mir ViladrichJosé Maria García García
Oct 10, 2015·Applied Health Economics and Health Policy·Shankar PrinjaStephen Jan
Jan 7, 2020·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Neil E RensJason R Andrews
Mar 15, 2015·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Melissa A BriggsAnand Date
Oct 7, 2016·AIDS Research and Therapy·Narendran GopalanSrikanth Tripathy
Apr 6, 2018·AIDS Research and Human Retroviruses·Kenneth A FreedbergRochelle P Walensky
Sep 15, 2020·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Yuli L HsiehAmber Kunkel
Nov 13, 2020·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Yuli L HsiehAmber Kunkel

❮ Previous
Next ❯

Software Mentioned

YRG CARE

Related Concepts

Related Feeds

Antitubercular Agents (ASM)

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.

Antitubercular Agents

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.